JP2006511520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511520A5 JP2006511520A5 JP2004559355A JP2004559355A JP2006511520A5 JP 2006511520 A5 JP2006511520 A5 JP 2006511520A5 JP 2004559355 A JP2004559355 A JP 2004559355A JP 2004559355 A JP2004559355 A JP 2004559355A JP 2006511520 A5 JP2006511520 A5 JP 2006511520A5
- Authority
- JP
- Japan
- Prior art keywords
- prophylaxis
- inhibiting
- risk
- reducing
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 230000000271 cardiovascular Effects 0.000 claims 1
- 201000001084 cerebrovascular disease Diseases 0.000 claims 1
- 201000008739 coronary artery disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
Claims (1)
- 血清コレステロール値を低下させ；または動脈硬化を治療し、阻止し、若しくは予防し；または心血管現象若しくは症状、冠動脈疾患、脳血管疾患を治療し、若しくはその危険性を低下させるための、請求項１の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/316,424 US20040115265A1 (en) | 2002-12-11 | 2002-12-11 | Multilayered tablet containing pravastatin and aspirin and method |
| PCT/US2003/038774 WO2004052289A2 (en) | 2002-12-11 | 2003-12-03 | Multilayered tablet containing pravastatin and aspirin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006511520A JP2006511520A (ja) | 2006-04-06 |
| JP2006511520A5 true JP2006511520A5 (ja) | 2006-12-14 |
Family
ID=32505946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559355A Pending JP2006511520A (ja) | 2002-12-11 | 2003-12-03 | プラバスタチンおよびアスピリン含有多層錠および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040115265A1 (ja) |
| EP (1) | EP1581194B1 (ja) |
| JP (1) | JP2006511520A (ja) |
| AT (1) | ATE401061T1 (ja) |
| AU (1) | AU2003297689A1 (ja) |
| CY (1) | CY1108414T1 (ja) |
| DE (1) | DE60322264D1 (ja) |
| DK (1) | DK1581194T3 (ja) |
| ES (1) | ES2308040T3 (ja) |
| IS (1) | IS2877B (ja) |
| MY (1) | MY140947A (ja) |
| NO (1) | NO338696B1 (ja) |
| PL (1) | PL206190B1 (ja) |
| PT (1) | PT1581194E (ja) |
| SI (1) | SI1581194T1 (ja) |
| TW (1) | TWI361700B (ja) |
| WO (1) | WO2004052289A2 (ja) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2522708C (en) | 2003-04-29 | 2013-05-28 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| US8163797B2 (en) * | 2003-12-31 | 2012-04-24 | Actavis Elizabeth Llc | Method of treating with stable pravastatin formulation |
| EP1830832A1 (en) * | 2004-12-30 | 2007-09-12 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
| US20060251722A1 (en) * | 2005-05-03 | 2006-11-09 | Novavax, Inc. | Multi-component vitamin and mineral supplement for the optimal absorption of components |
| JP2009507019A (ja) * | 2005-09-02 | 2009-02-19 | ジェンザイム・コーポレーション | リン酸塩を除去する方法およびそれに使用される重合体 |
| CA2626734A1 (en) * | 2005-11-08 | 2007-05-18 | Genzyme Corporation | Magnesium-containing polymers for the treatment of hyperphosphatemia |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| WO2007072060A2 (en) * | 2005-12-23 | 2007-06-28 | Cipla Limited | Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film |
| WO2007073702A2 (es) | 2005-12-29 | 2007-07-05 | Osmotica Corp. | Comprimido multicapa con combinación de triple liberación |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| WO2008005217A2 (en) * | 2006-07-05 | 2008-01-10 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
| US8765178B2 (en) * | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| TWI504419B (zh) * | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | 層狀醫藥調配物 |
| JP2010508997A (ja) | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | 減量薬を投与するための方法 |
| ES2841379T3 (es) | 2007-03-13 | 2021-07-08 | Jds Therapeutics Llc | Procedimientos y composiciones para la liberación sostenida de cromo |
| WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
| ES2659716T3 (es) * | 2007-10-12 | 2018-03-19 | Ferring International Center S.A. | Proceso para la fabricación de un producto farmacéutico que comprende ácido cítrico, óxido de magnesio, bicarbonato potásico y picosulfato sódico, composición farmacéutica que comprende gránulos obtenidos por tal proceso y productos intermedios de la misma |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| RU2616496C2 (ru) | 2010-01-11 | 2017-04-17 | Ориксиджен Терапьютикс, Инк. | Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты) |
| TR201005325A2 (tr) | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
| KR20120068277A (ko) * | 2010-12-17 | 2012-06-27 | 한미사이언스 주식회사 | ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제 |
| KR102068216B1 (ko) * | 2011-01-28 | 2020-01-20 | 인터치 테크놀로지스 인코퍼레이티드 | 이동형 원격현전 로봇과의 인터페이싱 |
| DK2858640T3 (da) | 2012-06-06 | 2020-06-29 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko |
| EP2810644A1 (en) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
| MX2018009748A (es) | 2016-02-11 | 2019-02-07 | Nutrition 21 Llc | Composiciones que contienen cromo para mejorar la salud y el estado físico. |
| JP7109748B2 (ja) * | 2018-12-11 | 2022-08-01 | 日本ジェネリック株式会社 | アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4590183A (en) * | 1985-04-22 | 1986-05-20 | Sterling Drug Inc. | Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin |
| JP3172749B2 (ja) * | 1992-02-17 | 2001-06-04 | ライオン株式会社 | イブプロフェン含有製剤 |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| IT1264517B1 (it) * | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| AU736951C (en) * | 1998-03-19 | 2003-02-20 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
-
2002
- 2002-12-11 US US10/316,424 patent/US20040115265A1/en not_active Abandoned
-
2003
- 2003-12-03 EP EP03812825A patent/EP1581194B1/en not_active Expired - Lifetime
- 2003-12-03 JP JP2004559355A patent/JP2006511520A/ja active Pending
- 2003-12-03 DK DK03812825T patent/DK1581194T3/da active
- 2003-12-03 DE DE60322264T patent/DE60322264D1/de not_active Expired - Lifetime
- 2003-12-03 AU AU2003297689A patent/AU2003297689A1/en not_active Abandoned
- 2003-12-03 PT PT03812825T patent/PT1581194E/pt unknown
- 2003-12-03 WO PCT/US2003/038774 patent/WO2004052289A2/en active Application Filing
- 2003-12-03 SI SI200331302T patent/SI1581194T1/sl unknown
- 2003-12-03 ES ES03812825T patent/ES2308040T3/es not_active Expired - Lifetime
- 2003-12-03 AT AT03812825T patent/ATE401061T1/de active
- 2003-12-03 PL PL377265A patent/PL206190B1/pl unknown
- 2003-12-08 TW TW092134590A patent/TWI361700B/zh active
- 2003-12-10 MY MYPI20034728A patent/MY140947A/en unknown
-
2005
- 2005-06-07 NO NO20052734A patent/NO338696B1/no not_active IP Right Cessation
- 2005-06-10 IS IS7889A patent/IS2877B/is unknown
-
2008
- 2008-10-14 CY CY20081101137T patent/CY1108414T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511520A5 (ja) | ||
| ATE516285T1 (de) | Dihydropyridinonderivate | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| NO20071930L (no) | t4Metoder og sammensetninger til behandling av hyperlipidemi. | |
| GB2414933B (en) | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis | |
| PL2482078T3 (pl) | Diagnozowanie choroby sercowo-naczyniowej | |
| NO20070247L (no) | Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase | |
| IL189500A (en) | 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p | |
| DE50311502D1 (de) | Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung | |
| NO20081016L (no) | Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser | |
| EP1848432A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES COMPRISING OBESITY, DIABETES, METABOLIC SYNDROMES, NEURODEGENERATIVE DISEASES, AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION | |
| NO20041452L (no) | 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer. | |
| GB0514501D0 (en) | Pharmaceutical compounds | |
| WO2006025924A3 (en) | Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof | |
| CL2007003690A1 (es) | Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas. | |
| WO2008034796A3 (en) | Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors | |
| JP2003526626A5 (ja) | ||
| JP2008519810A5 (ja) | ||
| WO2006138043A3 (en) | Method and compositions for the treatment of diabetes and related complications | |
| WO2004024167A3 (fr) | Utilisation de prebiotiques, preferentiellement le glucooligosaccharide, pour la prevention de l’installation du diabete de type ii | |
| EP1896074A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CORONARY ARTERY DISEASE | |
| NO20012831D0 (no) | Diazepinoindoler for behandling av kronisk obstruktiv lungesykdom | |
| JP2007512260A5 (ja) | ||
| GB2392386B (en) | Perfluorinated fatty acids for the treatment of diabetes, obesity, cardiovascular disease or as anti-tumour agents | |
| NL1032065A1 (nl) | Preparaat voor de preventie en behandeling van cardiovasculaire stoornissen. |